Print this page
breast
-
A Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations.
Protocol: 112008Principal Investigator:
- Marissa Botwinick
Applicable Disease Sites: Leukemia, not otherwise specified -
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT).
Protocol: 112106Principal Investigator:
- Scott A Moerdler
Applicable Disease Sites: Kidney -
A Phase 2 Study of Blinatumomab in Combination with Nivolumab, a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged < 1 to < 31 Years Old with First Relapse.
Protocol: 112011Principal Investigator:
- Richard A Drachtman
Applicable Disease Sites: Any Site -
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT).
Protocol: 112106Principal Investigator:
- Scott A Moerdler
Applicable Disease Sites: Kidney -
A Phase 1/2 Trial of Selinexor (KPT-330) and Radiation Therapy in Newly-Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma (DIPG) and High-Grade Glioma (HGG).
Protocol: 112203Principal Investigator:
- Nehal Parikh
Applicable Disease Sites: Brain and Nervous System -
A Phase 1/2 Trial of Selinexor (KPT-330) and Radiation Therapy in Newly-Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma (DIPG) and High-Grade Glioma (HGG).
Protocol: 112203Principal Investigator:
- Nehal Parikh
Applicable Disease Sites: Brain and Nervous System -
Expanded Access Protocol: Umbilical Cord Blood Infusions for Children with Brain Injuries
Protocol: 112207Principal Investigator:
- Archana Sharma
Applicable Disease Sites: Any Site -
A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-Oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma.
Protocol: 112305Principal Investigator:
- Richard A Drachtman
Applicable Disease Sites: Hodgkin Lymphoma -
Expanded Access Protocol: Umbilical Cord Blood Infusions for Children with Brain Injuries
Protocol: 112207Principal Investigator:
- Archana Sharma
Applicable Disease Sites: Any Site -
A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-Oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma.
Protocol: 112305Principal Investigator:
- Richard A Drachtman
Applicable Disease Sites: Hodgkin Lymphoma -
A Phase 3 Study of Dinutuximab Added to Intensive Multimodal Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma.
Protocol: 112404Principal Investigator:
- Nehal Parikh
Applicable Disease Sites: Brain and Nervous System -
A Phase 2 Study Using Chemoimmunotherapy with Gemcitabine, Cisplatin and Nivolumab in Newly Diagnosed Nasopharyngeal Carcinoma (NPC).
Protocol: 112405Principal Investigator:
- Scott A Moerdler
Applicable Disease Sites: Lip, Oral Cavity and Pharynx -
A Phase 3 Study of Dinutuximab Added to Intensive Multimodal Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma.
Protocol: 112404Principal Investigator:
- Nehal Parikh
Applicable Disease Sites: Brain and Nervous System -
A Phase II Trial Evaluating Chemotherapy followed by Response-Based Reduced Radiation Therapy for Patients with Central Nervous System Germinomas.
Protocol: 112409Principal Investigator:
- Nehal Parikh
Applicable Disease Sites: Brain and Nervous System -
A Phase 2 Study Using Chemoimmunotherapy with Gemcitabine, Cisplatin and Nivolumab in Newly Diagnosed Nasopharyngeal Carcinoma (NPC).
Protocol: 112405Principal Investigator:
- Scott A Moerdler
Applicable Disease Sites: Lip, Oral Cavity and Pharynx -
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT).
Protocol: 112504Principal Investigator:
- Scott A Moerdler
Applicable Disease Sites: Any Site